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ABSTRACT
Dual antiplatelet therapy has been proven effective to reduce recurrent cardiovascular eventin 
patients with coronary artery disease and recommended as standard therapy for acute coronary 
syndrome and patients who underwent percutaneous coronary intervention. The adverse clinical 
occurrence in patients who taking aspirin and clopidogrel associates with antiplatelet non 
responsiveness, in addition to repetitive bleeding incident in such a way that platelet reactivity 
and genetic polymorphisms investigation rises intense interest. Resistance to antiplatelet or 
antiplatelet non responsiveness means a phenomenon in which antiplatelet drug fails to deliver 
pharmacological target and it is determined by platelet function measurement. Recent laboratory 
methods have been developed to diagnose antiplatelet resistance, but none of them was 
considered as standard tool since its wide inter-individual variability and poor correlation between 
them. The mechanism of antiplatelet resistance is not fully understood, multifactorial, involving 
pharmaco dynamic and pharmacokinetic of the drugs. This review is aimed to comprehend the 
antiplatelet resistance mechanism and provide crucial information on managing patients who 
take dual antiplatelet treatment with adverse clinical events. 
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INTISARI
Terapi antiplatelet ganda telah terbukti efektif untuk menurunkan kejadian kardiovaskular 
berulang pada pasien dengan penyakit arteri coroner dan direkomendasikan sebagai terapi 
standar untuk sindroma coroner akut dan pasien yang menjalani intervensi coroner perkutan. 
Kejadian klinik buruk pada pasien yang mendapatkan aspirin dan klopidogrel berhubungan 
dengan sifat non reponsif terhadap antiplatelet, selain adanya perdarahan berulang yang 
menyebabkan pengkajian tentang reaktivitas platelet dan polimorfis megenetik menjadi 
meningkat. Resistensi terhadap antiplatelet atau nonresponsive terhadap antiplatelet berarti 
suatu fenomena dimana obat antiplatelet tidak mampu mencapai target farmakologi dan hal 
ini ditentukan oleh pengukuran fungsi platelet. Dewasa ini, metode pengukuran laboratorium 
telah dikembangkan untuk mendiagnosis resistensi antiplatelet, namun belum ada yang diterima 
sebagai alat standar karena adanya variabilitas antar individu dan korelasi yang buruk diantara 
alat-alat tersebut. Mekanisme resistensi antiplatelet tidak sepenuhnya dimengerti, multifaktor, 
melibatkan farmako dinamik dan farmako kinetic dari obat. Tinjauan pustaka ini bertujuan untuk 
mengetahui mekanisme resistensi antiplatelet dan memberikan informasi penting dalam tata 
laksana pasien yang mendapatkan terapi antiplatelet ganda dan mengalami kejadian klinik buruk.
INTRODUCTION
Antiplatelet drugs are widely used to reduce 
thrombosis process in atherosclerosis patients. 
There are three kinds of antiplatelet drug which 
have been proven their benefit to coronary 
artery disease (CAD), i.e. (i)cyclooxygenase 
(COX)-1 inhibitor such as aspirin, (ii) adenosine 
5’-diphosphate (ADP) antagonist receptor 
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such as thienopyridine (ticlopidin, clopidogrel, 
prasugrel), and (iii) GPIIb/IIIa antagonist such as 
abciximab, eptifibatide,and tirofiban. Aspirin and 
thienopyridinework selectively on inhibiting platelet 
activation and subsequent aggregation; aspirin in 
thromboxan A2 production through irreversibly 
COX-1 inhibition, while thienopyridinedisturbed 
ADP pathway through thrombocyte ADP receptor 
blockade. The prevention of platelet’s clumping 
result in reduction of atherothrombotic event patient 
with CAD.1,2,3
I n  add i t i on  to  the i r  advan tages , 
researchers reported significant antiplatelet 
deb i l i t iessuch as  low respons iveness 
(resistance), lack of platelet inhibition ability, 
variation of individual response, and lengthen 
time to recovery. Residual platelet reactivity 
is correlated with increased risk of major 
cardiovascular events.4 Chirumamilla et al. 
(2012) investigated the relationship of platelet 
reactivity and atherosclerotic burden in 
patients treated with percutaneous coronary 
intervention (PCI). That study suggested that 
an increased platelet reactivity on antiplatelet 
treatment was correlated with higher burden 
of CAD and plaque calcification.5 Antiplatelet 
resistance is also associated with repetitive 
bleeding events in CAD patients.6
THE INCIDENCE OF ANTIPLATELET 
RESISTANCE
The prevalence of antiplatelet resistance 
in different population with several methods 
of laboratory tests is various. Numerous 
studies report the prevalence of aspirin and 
clopidogrel resistance is about 5-60%, as 
shown on table 1 and 2. The results show a 
wide variation and poor consistency among 
those researches. Therefore, it is needed to 
evolve more studies to investigate the ideal 
laboratory test which can identify antiplatelet 
resistance and the patients who at risk of future 
adverse cardiovascular events.7
MECHANISM OF ACTION: ASPIRIN AND 
CLOPIDOGREL
Aspirin causes permanent inhibition of COX-
1 by acetylating a serine residue at position 530 with 
the result that prevent the changes of arachidonic 
acid (AA) to the unstable prostaglandin (PG) which 
is converted to thromboxan A2 (TXA2), a platelet 
agonisand vasoconstrictor. Clopidogrel is an 
inactive prodrug derived thienopyridine, converted 
into active form by hepatic P450 cytochrom 
enzyme, acts byirreversible antagonism of P2Y12 
adenosine diphosphate (ADP) receptor. Those 
dual antiplatelets therapy significantly decrease 
thrombotic events. The action’s mechanism of 
aspirin and clopidogrel are shown on figure 1.8
DEFINITION OF ANTIPLATELET RESISTANCE
European Society of Cardiology (ESC) 
Working Group on Thrombosis states that definition 
of antiplatelet resistance remains unclear since the 
standardized platelet function test has not been 
established to define whether it is responders or 
non-responders (resistance). The terminology of 
antiplatelet resistance consists of two features: 
clinical and laboratory. A patient who receives 
antiplatelet drug routinely but still experiences in 
cardiovascular event implied as clinical resistance. 
While laboratory resistance is defined when 
antiplatelet drug does not work properly to block 
platelet activation on in vitroexamination.9
Inter individual variability concept upon any 
agent may be described as follows, different effect 
with varied intensity on different subject regardless 
the same agent’s plasma concentration.  Absorbtion, 
distribution, metabolism (biotransformation) and 
elimination, known as pharmacokinetics, each 
contributes on plasma concentration variation 
and or active metabolites in any individual who 
receives the same dose. Biomechanical and 
physiological effects of the agent and its action 
mechanism, created complex relations with the 
given concentration and the clinical effect shown, 
called pharmacodynamics. Both pharmacokinetics 
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Table 1. Prevalence of aspirin resistance based on laboratory assay7
Source of table: Saraf et al. (2009)7
Table 2. Prevalence of clopidogrel resistance based on laboratory assay7
Source of table: Saraf et al. (2009)7
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and pharmacodynamics work as the basis to 
understand successful rate of therapy and its side 
effect (figure 2).10
MECHANISM OF ANTIPLATELET RESISTANCE
When coronary artery plaques ruptur, 
thrombogenic substrate is released into blood 
circulation and result in the activation and 
aggregation of platelet. On PCI procedures 
(especially when balloon or stents are deployed), 
patients are at high risk of thrombotic response 
due to vascular injury. Aspirin and clopidogrel are 
proven to reduce in stent thrombosis or restenosis 
after drug-eluting stenting. However, antiplatelet 
non-responsiveness still occurs in some patients 
on standard dual antiplatelet therapy. The 
mechanism of antiplatelet resistance is not fully 
understood.11  High individual response variability 
on antiplatelets agents involve many factors, 
such as non-compliance and low absorption.4 
Other mechanisms responsible to antiplatelet 
resistance include lowering bioavailability, 
genetic variations, increased platelet turnover, 
activation of platelet from other pathway, and 
individual variation (table 3).7
MECHANISM OF ASPIRIN RESISTANCE
Pharmacodynamics resistance of aspirin 
caused by change of aspirin target enzyme, 
COX-1, and increasing the dosein vitro 
did not significantly alter thromboxan-A2 
production. This phenomenon refers to 
Figure 1.Antiplatelet site of action
Source: Fox et al.(2013)8
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Figure 2. Pharmacokinetics and pharmacodynacis which influenced drug clinical outcome.
This figure is modified from Rocca and Petrucci (2012)10.
laboratory resistance which aspirin does not 
block properly with in vitro platelet reactivity. 
Pharmacokinetics resistance was a condition 
caused by limited supply of active agents on 
plasma that caused low therapeutics response 
(such as low dose or absorption change) that 
improved significantly by adding aspirin in vitro 
dosage.12
In the clinical practice, nonadherence is 
probably the most frequent cause of aspirin 
nonresponsiveness. The lack of aspirin effect 
is due to the patient not taking the drug 
regularly or prematurely discontinue it. Aspirin 
discontinuation may not improve efficacy, but 
may raise bleeding risk and correlated with 
threefold increase in adverse cardiovascular 
events.12,13  Enteric coated aspirin is considered 
as a culprit of lower effectivity especially on 
obese patients because its tendency of low 
bioavaibility and bad absorption due to high-
pH condition in the small intestine.12,13,14,15 
The reducing bioavailibility of aspirin by 
gastrointestinal mucosal esterases may also 
occur when it takes together with proton pump 
inhibitor.12 Competition with other NSAIDs 
connected with Ser 530 enzim COX-1, in 
advanced causing irreversible acethylation and 
enzyme inactivation. It is caused by location of 
binding site both aspirin and NSAIDs  are within 
a hydrophobic channel in COX enzyme.13,14.
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In pharmacodynamics perspective, 
production of residual thromboxan by COX-1 
and COX-2 is thought to be responsible for 
aspirin resistance. Furthermore, enhanced 
platelet turnover (primary or secondary) or high 
interaction between platelet and vessel wall 
(such as diabetes) may cause more relevant to 
COX-1 activity than aspirin effectiveness. COX-2 
overexpressionson platelet, megakaryosites and 
its upregulations on monocytes, macrophages 
and vascular endothel cells (as seen in diabetes, 
hyperlipidemia, smoking, and heart failure) may 
cause biosynthesis thromboxan elongation, 
which later could contribute to aspirin resistance. 
This conditions may be caused by overproduction 
of prostaglandin-like compound which relate 
with oxygen free-radicals nonenzymatic 
acidarachidonic lipid peroxidation.12 Genetic 
factors also correlate with aspirin resistance. Its 
includes genetic polymorphisms of thromboxan 
synthesis, P1A1/A2 (encoded gene of platelet 
membrane’s GPIIIa), COX-1 and platelet 
collagen-receptor’s GPIa/IIa, and polymorphisms 
which cause overexpression of COX-2 mRNA in 
platelets and endothelial cells.12
MECHANISM OF CLOPIDOGREL RESISTANCE
There are multiple etiologies which 
contribute the nonresponsiveness to clopidogrel. 
Its proposed mechanisms include bioavailability, 
cellular factors, genetic polymorphism, and other 
factors such as body mass index, diabetes, 
hypercholesterolemia, and smoking (table 
4).11,13 The lack of clopidogrelbio availibility 
Table 3 .Underlying mechanisms of antiplatelet resistance7
Bioavailabilitasdecrement • Incompliance
• Inadequate dosage
• Low absorption (enteric coated aspirin)
• Increased metabolism
• Other drug interaction (involving P-450 CYP3A4 cytochrome system 
for conversion onto active metabolyte) 
• Other drug interaction (NSAIDs)
Genetics Variations • Gene COX1 mutation
• Gene COX1, glycoprotein(GP) Ia/IIa, GP IIIa, P2Y1 or P2Y12 
polymorphism
• Gene P-450 CYP3A polymorphism (for clopidogreland any other 
prodrug that metabolised with the system)
• Platelet glycoprotein receptor polymorphism
• Platelets and endothel cell’s COX 2 overexpression
Enhanced platelet turnover • Increment of bone marrow’s platelet production 
• Unexposed aspirin and clopidogrel new platelets (case example, 
tranfusion)
• Platelet activation induced by cigars.
• Platelet activation induced by erythrocyte increment. 
Platelet activation from 
alternative pathway 
• TXA2 synthesis induced by cytokines, oxidative stress or nucleated 
cells
• Platelet activation induced by cathecolamine caused by exaggerated 
physical or mental stress. 
• High incidencee of shear stress, collagen, thrombin and other 
platelet activation pathway. 
Individual variation • Diabetes or insulinresistance
• Hypercholesterolaemia
• Hypertension
• Old age
• Obesity
• Sex 
Source of table: Saraf et al. (2009)7
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commonly due to non adherence patients, 
underdosing, and lowering prodrug intestinal 
absorption. Clopidogrel may interact with 
lipophilic statin, calcium-channel blocker, 
and omeprazole result in changes in hepatic 
cytochrome P450 isoenzymes activity and 
responsible on interfering clopidogrel action.13 
Interaction with benzodiazepine and selective 
serotonin reuptake inhibitor (SSRI) are also able 
to decrease clopidogrel biovailability.17
The genetic factors which affect the 
clopidogrel response are polymorphisms 
of cytochrom P450, variat ions in P2Y12 
receptor density, andcarriers of disabled 
CYP2C19681G>A*2.13 Hulot et al (2006) 
conducted pharmacogenetic study to figure out the 
mechanism of clopidogrel hyporesponsiveness 
which related to genetic variation. 
They concluded that CYP2C19*2 loss-
of-function allele was correlated with poor 
antiplatelet responsiveness of clopidogrel in 
young healthy male volunteers. The capability 
of clopidogrel to impede ADP-induced platelet 
aggregation demonstrates a wide individual 
variabiality.18,19 Different platelet response to ADP 
which not increased by clopidogrel administration 
is also accounted as individual variability.20
L A B O R AT O RY  M E A S U R E M E N T  O F 
ANTIPLATELET RESISTANCE
Guidelines of myocardial revascularization 
(2014) published by ESC states that platelet 
function test or genetics is considered on high 
risk conditions such as stent thrombosis history, 
incompliance, resistance suspicion, and high risk 
bleeding (class recommendation IIb), though 
routine examination before and after stent 
implantation is not recommended.21
In vivo (bleeding time) and in vitro (light 
transmission aggregometry/LTA, PFA-100 system, 
ultegrarapidplatelet function assay-ASA) platelet 
function are not always reflecting drug ability to 
reach its pharmacology target.22  Various methods 
is developed to obtain the most appropriate 
measurement of platelet function in clinical 
practice.23
Table 4. Factors influence variability of clopidogrel response7
Bioavailability • Nonadherence patient
• Drug interaction (lipophilic statins, omeprazole)
• Poor absorption
• Underdosing
Cellular factor • Enhanced platelet turnover
• Increased platelet sensitivity to ADP and collagen
• Reduced activity CYP3A 
• Increased exposure ADP
• Upregulation of P2Y12 pathways 
• Upregulation of P2Y-independent pathways: collagen, 
thrombin, epinephrin, TXA2
Genetic factor • Polymorphisms of P450(CYP2C19681G>A[*2,*3,*4, and 
*5]
• Polymorphisms of P2Y1
• Polymorphism of P2Y12
• Polymorphism GPIa
• Polymorphism GP IIIa
Other factors • Increased body mass index
• Diabetes
• Hiperinsulinemia
• Hypercholesterolemia
• Smoking
Source of table: Saraf et al. (2009)7
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T h e  g o l d  s t a n d a r d  o f 
ant ip late let  resistanceassay is  LTA or 
turbidometricaggregometry, which based on 
platelet aggregation measurement between the 
agent and its agonis, as AA and ADP for aspirin, 
or ADP only for clopidogrel, prasugrel, or ticagrelor. 
Recently, Verify Now®and vasodilator stimulated 
phosphoprotein (VASP) phosphorylationassay is 
considered as more practically for clinical interest, 
Table 5. Various methodes of platelet function assessment 23
Abbreviations: Beta-TG, beta-thromboglobulin; Pls, plasma; PRP, platelet-rich-plasma; ROTEM, rotational 
thromboelastometry; TEG, thromboelastography; TxA2, thromboxane A2; WB, whole blood; W-Plt, washed 
platelets; VWD, Von Willebrand disease.
Source of table: Saraf et al. (2009)7
due to LTAhas a low reproducibility, interindividual 
variability on ADP induced platelets aggregation 
baseline, and the logistical condition make a 
difficulty to use in daily practice.24
Ultegra Rapid Platelet Function Assay 
(RPFA)-Verify Now® is a simple, rapid (less than 
5 minutes), user-friendly, high reproducibility, 
and point-of-care assessment which use AA or 
propylgallate to measure aspirin effects and ADP 
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to find out the effect of P2Y12 inhibitor.24 Platelet 
function is assessed from the ability of activated 
platelet to bind fibrinogen which is detected by 
turbidimetric-based optical. Using light source, 
blood specimens is added to mixing chamber 
(cartridge) which contains fibrinogen-coated 
beads and a specific agonist. Clotting of functional 
platelets will raise the light transmission and the 
amount of fibrinogen binding by the activated 
platelets is determined. Three different assays are 
available to verify the inhibition of platelet function 
by anti-platelet drugs (GPIIb/IIIa inhibitor, aspirin, 
and clopidogrel). The result of aspirin and P2Y12 
test is reported as Aspirin Reaction Unit (ARU) and 
P2Y12 Reaction Unit (PRU), respectively.23,25 The 
cutt-off value of aspirin and clopidogrel resistance 
are ≥ 550 ARU and ≥ 240 PRU.6
M A N A G E M E N T  O F  A N T I P L AT E L E T 
RESISTANCE
Experts recommend three strategies to 
overcome antiplatelet resistance: increasing 
the dosage, adding other agent (such as 
gylcoprotein IIb/IIIa inhibitor, cilostazol), or 
substituting with more potent agent (such as 
prasugrel, ticagrelor).6 Alegria-Barrero et al 
(2010) convey an algorithm on overcoming 
antiplatelet resistance in patient undergo PCI 
(figure 3). After PCI procedure, patient receives 
dual antiplatelet drug (aspirin 100 mg and 
clopidogrel 75 mg). When aspirin or clopidogrel 
resistance is indicated, increase aspirin dosage 
up to 325 mg or clopidogrel 150 mg, respectively. 
It may also be switched with trifusal for aspirin 
resistance or prasugrel/ticagrelor/prasugrel for 
clopidogrel resistance.26
Neubaueret al. (2011) investigate 504 
patients following PCI in single center study 
whoreceived 500 mg aspirin (loading dose), 
continued with 100 mg per 24 hour and 600 mg 
clopidogrel (loading dose), continued with 75 
mg per 24 hour. All participants undergo whole 
blood aggregometry examination > 48 hours 
(no more than 72 hour) after stent implantation. 
The researcher applies the tailored algorithm 
on managing antiplatelet resistance which 
called “The Bochum clopidogrel and aspirin 
plan (BOCLA-Plan)”. Study result identified 
30,8% clopidogrel low-responders (CLR) and 
19,4% aspirin low-responders (ALR). Aspirin 
dosage adjustment gradually at 300 mg/day, 
then 500 mg/day, resulted on 5,4% residual 
ALR. This means aspirin maintenance dose 
modification is adequately success for ALR. 
Meanwhile, 69%CLR patients are successfully 
treated with increased dosage of clopidogrel (150 
mg/24 hour). The remaining 12.7% CLR who is 
contraindicated with prasugrel or inavailability 
of prasugrel, show adequate response with 
ticlopidine.Other CLR patients given prasugrel 
has not shown residual properties yet.This 
algorithm implementation decreasing the CLR 
prevalence by 86.6%.27
The former research, Aspirin Induced 
Platelet Effect (ASPECT) research on stable 
coronary artery disease, showed ALR decrement 
Figure 3. Algorithm of antiplatelet resistance 
mangement.
Reprinted with permission from Alegria-Barrero 
(2010)26
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by increasing aspirin up to 325 mg/24 hour.28 
Practice guideline for PCI from ACC/AHA/SCAI 
(2005) states that patients in whom subacute 
thrombosis may be fatal (such as unprotected left 
main, bifurcating left main, or last patent coronary 
vessels), platelet aggregation assessment may be 
considered and if it reveales inhibition of platelet 
agregation < 50%, clopidogrel dosage should be 
increased up to 150 mg/24 hour (class IIb, LoE : 
C).29
Aspirin resistance might be suppressed 
by minimalizing thromboxan production and 
activity or any other platelet activation pathway. 
Stop smoking, body weight reduction and routine 
physical training are mentioned to increase 
platelet function. Other clinical condition as 
hyperlipidemia, diabetes mellitus, hypertension, 
cardiac failure, and inflammation disturbances 
also disrupt aspirin activity. Incompliance, 
avoidance of agents interfere with aspirin 
absorption as proton pump inhibitor and enteric 
coated aspirin, agent decrease pharmacokinetics 
as NSAID, has its benefit on reducing resistance.12
Higher platelet exchange increase the 
dose needed for aspirin, as American Diabetes 
Association recommended. Dose 75-162 mg/ 24 
hour on diabetic patient with cardiovascular risk 
increased (as primary prevention) such as male 
> 50 yo, female > 60 yo with minimal 1 risk factor 
of atherosclerotics, or secondary prevention for 
those already diagnosed with atherosclerotic 
vascular disease.24 The proposed algorithm on 
handling aspirin resistance is shown on figure 4.
CONCLUSION
Resistance to antiplatelet means a 
phenomenon in which antiplatelet drug fail 
to deliver pharmacological target and it is 
determined by platelet function measurement. 
Antiplatelet resistance is associated with recurrent 
adverse cardiovascular events, higher burden 
of CAD, plaque calcification, and repetitive 
bleedingoccurences. Studies develop various 
laboratory methods to recognize antiplatelet 
resistance, but none of them is considered 
as standard tool since its wide inter-individual 
variability and poor correlation between them. The 
published guidelines does not recommend to check 
the platelet function test routinely in periprocedural 
of PCI, unless the patient on high risk situation in 
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whom subacute thrombosis may be fatal. 
T h e  m e c h a n i s m  o f  a n t i p l a t e l e t 
resistance is involving pharmacodynamic 
and pharmacokinetic of the drugs, include 
incompliance, low absorption, high individual 
response variabil i ty, genetic variations, 
increased platelet turnover, and activation of 
platelet from other pathway. Experts recommend 
tailored strategies to overcome antiplatelet 
resistance: increasing the dosage, adding (such 
as gylcoproteinIIb/IIIa inhibitor, cilostazol) or 
substituting with other agent (such as trifusal 
for aspirin resistance; prasugrel or ticagrelor for 
clopidogrel resistance), and control the other 
possible modifiable mechanisms.
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